ALLIANCE PHARMA PLC

Major Shareholding Notification • Oct 25, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3666R

Alliance Pharma PLC

25 October 2013

For immediate release	25 October 2013

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Major Interest in Shares

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, was informed on 22 October 2013 that following recent conversions of the Company's 8% Convertible Unsecured Loan Stock into ordinary shares of 1p each in the Company ("Ordinary Shares"), Nigel Wray's holding of Ordinary Shares, which is unchanged at 38,106,995, now represents 14.9% of the Company's issued share capital.

Mr Wray's Ordinary Shares are held as follows:

Nominee	Number of ordinary shares
Pershing Nominees Limited Roy Nominees Limited	13,442,407 24,664,588

For further information:

### Alliance Pharma plc	### + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
### Buchanan	### + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Oliver Cardigan
Corporate Broking: David Poutney

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFEUFMLFDSEIS